G-Zero Cedes to Start-up G1 in Small-Molecule Inhibitors

Based on discoveries licensed from the University of North Carolina at Chapel Hill, privately held G1 Therapeutics Inc. is trained on the discovery and development of small molecules targeting proteins associated with cell proliferation and growth in cancer therapy and biodefense.